Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors

Ishwaria M. Subbiah1, Chad Tang2, Arvind Rao3, Gerald S. Falchook4, Vivek Subbiah5, Apostolia M. Tsimberidou5, Daniel Karp5, Razelle Kurzrock6 and David S. Hong5

1Department of Palliative, Rehabilitation and Integrative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
4Sarah Cannon Research Institute at HealthONE, Denver, CO, USA
5Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA
6Center for Personalized Cancer Therapy and Clinical Trials Office, Moores Cancer Center, University of California, San Diego, CA, USA

Correspondence to: Ishwaria M. Subbiah, email: isubbiah@mdanderson.org

Keywords: geriatric oncology; elderly; VEGF inhibitors; older adults; phase I trials

Received: May 19, 2018 Accepted: May 24, 2018 Published: June 22, 2018

Copyright: Subbiah et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Background: Older adults aged 65 years and above remain underrepresented in cancer clinical trials. We hypothesized that older participation in early phase trials with VEGF/VEGFR (VEGF/R) inhibitors was lower than cancer prevalence in this group and lower than other age groups (middle age, adolescent/young adults [AYA]).

Results: Of 1489 patients, 278 were older adults (18%, median age 68.9y), 220 AYA (15%, median age 32.6 y), 991 middle age (67%, median age 53.8 y). Common malignancies included gastrointestinal (n = 438, 29%), gynecologic (n = 234, 16%), and thoracic/head/neck (n = 216, 15%). Median time to treatment failure did not vary significantly between the 3 age-based cohorts (3m in older adults, 3.5 m middle age, 3.3 m AYA). OR of achieving clinical benefit in older adults vs middle age (OR 1.10, p 0.19 [two-tailed], p 0.09 [one-tailed]) and AYA vs middle age (OR 0.85, p 0.31 [proportions z-test, two tailed], p 0.15 [one-tailed]) showed no significant differences.

Conclusions: Older adults accounted for <20% of participants on phase I clinical trials with VEGF/R inhibitors but those who participated were just as likely to achieve a clinical benefit as AYA and middle age patients. These findings merit further exploration into patient selection for early phase trials.

Methods: We identified and separated patients treated on VEGF/R-inhibitor-based phase I trials from 12/1/2004–07/31/2013 into 3 age-based cohorts, AYA (15–39y), middle age (40–64 y), older adults (65 y+). We analyzed clinical/treatment characteristics and response outcomes, calculating the odds ratios (OR) of clinical benefit (defined as SD ≥ 6months, PR, CR) for older adults and AYAs versus middle age participants.
INTRODUCTION

Tumor angiogenesis and its associated role in cancer growth and metastases have long been identified as therapeutic targets in the management of cancer [1, 2]. Agents targeting vascular endothelial growth factor family and their receptors (VEGF/R), including anti-VEGFA monoclonal antibodies and a host of receptor tyrosine kinase inhibitors, have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA), first starting with bevacizumab in combination with an intravenous 5-fluorouracil (5-FU)-based chemotherapy regimen for metastatic colorectal cancer [3, 4]. The approved indications include the treatment of cancers of the gastrointestinal tract, hepatobiliary system, renal cell carcinoma, thyroid cancers, and soft tissue sarcoma [5]. Furthermore the drug development pipeline is robustly populated by novel agents with VEGF/R inhibition, particularly as novel combinations with immunotherapies [6].

Given this prominent presence of antiangiogenic agents in the anticancer armamentarium, the characteristics of patients participating on the early phase clinical trials of these agents becomes of particular concern [7]. Specifically, precedent dictates that the age distribution of patients participating on cancer clinical trials overall does not reflect the age distribution of the general population with advanced cancer, both in incidence and prevalence. [8, 9]. Indeed despite accounting for a majority of new cases of cancer as well as cancer-related mortality in the United States, older adults aged 65 and above have been consistently underrepresented in oncology clinical trials [10, 11]. This age-based discrepancy in participation of older adults is more so evident in early phase I/II clinical trials, particularly with novel agents [12]. Indeed the heterogeneity among trials participants in early phase trials becomes of particularly high significance given that these trials are meant to identify therapy-associated toxicities of all severities and preliminary insight into efficacy.

To that end, we hypothesized that older adults aged 65 years and above remain underrepresented on phase I trials with drugs targeting VEGF/R. Furthermore, we hypothesized that older adults who do participate on these phase I trials have a comparable probability of achieving clinical benefit when compared to middle age patients and adolescent/young adult (AYA) patients.

RESULTS

Patient characteristics

Overall, we identified 1,489 consecutive patients who were treated on a phase I clinical trial with drugs that have a component of VEGF/R inhibition (Table 1). Of these patients, 278 (18%) were older adults aged 65 years and above (median age 68.9y, range 65 to 86.3 years), 991 (67%) were middle age (median age 53.8 years, range 40 to 64.9 years), and 220 (15%) were adolescent and young adults (AYA, median age 32.6 years, range 15.4 to 39.9 years). There were no significant differences in gender among the older adults and middle age cohorts, with women representing 46% of older adult patients treated on trial and 55% of middle age patients. However among the AYA subgroup, the gender gap was more evident with women comprising a larger percentage of trial participants than men (67% women, 33% men).

All trial participants were heavily pretreated with a median number of prior therapies being 3 in all three-age based cohorts. Overall, among the 1,489 patients, the most common malignancies were gastrointestinal (n = 438, 29%), gynecologic (n = 234, 16%), and thoracic/head/neck (n = 216, 15%). Gastrointestinal tumors were the most common primary malignancy among the middle age (31%, n = 306) and older adults (35%, n = 97). However the gynecologic cancers (19%, n = 41) and sarcomas (18%, n = 39) were more common than gastrointestinal primaries (16%, n = 35) among the AYA subgroup in comparison to the middle age and older adults.

Treatment characteristics

Overall, 472 of the 1,489 patients (32%) were treated on protocol with single agents, while 1017 (68%) were given a combination therapy with 2 or more agents (Table 2). Specifically, 648 (44%) patients received two agents, 362 (24%) received three, and 7 (<1%) received four. Among the 278 older adults, 98 (35%) received monotherapy compared to 298 (30%) of 991 middle age patients and 76 (35%) of 220 AYA patients. Of the 278 older adults, 180 (65%) received combination therapy with either two (47%, n = 132), three (17%, n = 46), or four (<1%, n = 2) drugs. Overall, 575 (69%) of the 1489 patients received a novel agent that, at that time, was not FDA-approved for any indication, including 110 (40%) of the older adults, 369 (37%) of the middle age participants, and 96 (44%) of the AYAs; those drugs that were FDA-approved were under trial here in a dose-finding study for new indications.

Overall, 1489 patients enrolled on 106 phase I trials that included at least one agent with anti-angiogenic activity and were consequently included in this analysis. All 106 trials enrolled patients with all advanced cancers, 75 (71%) were industry-sponsored while 31 (29%) were investigator-initiated studies. The studies themselves did not have an upper age limit but approximately 30% did exclude patients aged below 15 years. All trials were intended to obtain the maximum tolerated dose of the drug (or at least one of the drugs in a combination study) – this agent with the variable dosing was not universally the anti-angiogenic drug in a multi-drug combination phase I trial.

The monoclonal antibody bevacizumab (33%, n = 496) was the most common type of anti-angiogenic
agent given in our 1,489 trial participants with tyrosine kinase inhibitors (TKI) being the second (21%, n = 307). Of these 307 patients, the most common TKIs administered that had anti-angiogenic properties were sorafenib, given to 42% (n = 128) of patients. Also frequently used were cabozantinib (24%, n = 73), pazopanib (10%, n = 32) and a novel TKI targeting the VEGFR/PDGFR kinase family (9%, n = 28).

**Table 1: Characteristics of the 1,489 patients treated on an anti-VEGF/R-based phase I trial**

|                          | AYA (15–39 y) | Middle age (40–64 y) | Older adults (65+y) |
|--------------------------|---------------|----------------------|--------------------|
| n                        | 220 (15%)     | 991 (67%)            | 278 (18%)          |
| Age, median, years       | 32.6          | 53.8                 | 68.9               |
| Age, range, years        | 15.4–39.9     | 40.0–64.9            | 65.0–86.3          |
| Gender                   |               |                      |                    |
| Female                   | 148 (67%)     | 548 (55%)            | 127 (46%)          |
| Male                     | 72 (33%)      | 443 (45%)            | 151 (54%)          |
| #prior therapies, median (range) | 3 (0–15) | 3 (0–13) | 3 (0–13) |
| Primary cancer           |               |                      |                    |
| Breast                   | 20 (9%)       | 95 (10%)             | 14 (5%)            |
| Endocrine                | 17 (8%)       | 60 (6%)              | 13 (5%)            |
| Gastrointestinal         | 35 (16%)      | 306 (31%)            | 97 (35%)           |
| Genitourinary            | 7 (3%)        | 81 (8%)              | 20 (7%)            |
| Gynecologic              | 41 (19%)      | 160 (16%)            | 34 (12%)           |
| Melanoma                 | 25 (11%)      | 90 (9%)              | 30 (11%)           |
| Other                    | 5 (2%)        | 20 (2%)              | 17 (6%)            |
| Sarcoma                  | 39 (18%)      | 46 (5%)              | 10 (4%)            |
| Thoracic/Head/Neck       | 31 (14%)      | 133 (13%)            | 43 (15%)           |

**Table 2: Treatment characteristics of the three age-based cohorts**

|                          | AYA (15–39 y) | Middle age (40–64 y) | Older Adults (65+y) | Total   |
|--------------------------|---------------|----------------------|--------------------|---------|
| Total number of patients | 220           | 991                  | 278                | 1489    |
| Monotherapy              | 76 (35%)      | 298 (30%)            | 98 (35%)           | 479 (32%)|
| Combination therapy      | 144           | 693                  | 180 (65%)          | 1017 (68%)|
| 2 drugs                  | 90            | 426                  | 132 (47%)          | 648 (44%)|
| 3 drugs                  | 54            | 262                  | 46 (17%)           | 362 (24%)|
| 4 drugs                  | 0             | 5                    | 2 (<1%)            | 7 (<1%)  |
| Drug(s) given on protocol|               |                      |                    |         |
| Non-FDA approved agent   | 96 (44%)      | 369 (37%)            | 110 (40%)          | 575 (69%)|
| Bevacizumab              | 76            | 340                  | 80                 | 496 (33%)|
| TKI                      | 45            | 204                  | 58                 | 307 (21%)|
| Sorafenib                | 20            | 87                   | 21                 | 128 (42%)|
| Cabozantinib             | 7             | 51                   | 15                 | 73 (24%) |

Abbreviations: FDA Food and Drug Administration.

**Time to treatment failure (TTF)**

To recap, the overall time to treatment failure was defined as the time in months between the first day of the first cycle to the date off study due to clinical and/or radiographic progression or date of death if that preceded the anticipated date of restaging imaging. When comparing the time on study of the three age-based
cohorts, the median time to treatment failure on a phase I trial did not vary significantly between the 3 cohorts with the older adults being 3 months, the middle age patients being 3.5 months, and the AYAs being 3.3 months.

**Response on trial**

Over the 1489 patients treated on a phase I trial, 729 (49%) attained a stable disease (SD) per RECIST as their best response on trial, of whom 306 (21%) patients reached a prolonged SD of 6 months or longer (median duration 9.2 months; Table 3). Additional responders included 158 (11%) patients who attained a partial response (PR) with a median duration of response being 9.6 months and 8 (<1%) patients with a complete response (CR, median duration of response 37.4 months). Among the 278 older adults, 136 (49%) attained SD including 53 (19%) patients with prolonged SD of 6 months or more (median duration of response 9.0 months) and 23 (8%) attained a PR (median duration 7.4 months). Among middle age patients, 500 (50%) had an SD including 211 (21%) prolonged SD (median duration 9.2 months), 101 (10%) patients with a PR (median duration 10.8 months) and 6 (<1%) patients with a CR (median duration 29.3 months). In the 220-patient AYA cohort, 93 (42%) attained SD with 42 (19%) prolonged SD (median duration 9.7 months), 34 (15%) had a PR (median duration 9.5 months), and 2 patients had a CR lasting 36.2 months and 50.1 months. Overall, 78 (35%) AYA participants, 384 (32%) middle age patients and 119 (27%) older adults achieved a clinical benefit (CR + PR + SD ≥ 6 months).

**Odds ratio of achieving clinical benefit**

We then analyzed the likelihood of achieving a clinical benefit among the three age-based cohorts while on study. The odds ratio of achieving clinical benefit in older adults in comparison to middle age patients was 1.10, p 0.19 (two-tailed), p 0.09 (one-tailed). Similarly, the odds ratio of achieving clinical benefit in among the AYA patients versus middle age patients is 0.85, p 0.31 (proportions z-test, two-tailed), p 0.15 (one-tailed). No significant differences were found in the odds ratio or likelihood of attaining a clinically beneficial response between the older adults, AYA, and middle age cohorts.

**DISCUSSION**

Overall in our study, patients aged 65 years and above accounted for less than 20% of all participants on phase I clinical trials with VEGF/R inhibitors but those older adults who did participated were just as likely to achieve a clinical benefit of disease response as the other age-based cohorts (AYA and middle age patients). For older adults, the oncologic decision-making process takes on additional complexities in the context of age-related changes including decline in organ function, comorbidities as well as the surrogate assessments of frailty such as performance status as determined by the medical oncologist [15, 16]. Retrospectively, pooled analysis from randomized phase III studies of bevacizumab in metastatic colorectal cancer has shown that older adults who met the trial inclusion criteria assessing their medical fitness for participation had comparable progression-free survival and overall survival as the patients who were aged 65 and younger [11, 17]. The conscious identification of enrollment disparities of population subgroups such as older adults and women has led to a trend in recent years towards a greater representation of these groups in cancer clinical trials [18]. Prospectively, such improvements in older adult participation have been particularly recognized among non-small cell lung cancer patients participating in the National Cancer Institute cooperative groups trials, where the enrollment disparity of the older adults showed a considerable improvement over a 12-year period from 1990 to 2012 [19].

However, our findings suggest that such increases in participation may not have yet extended to early phase studies. With the advent of personalized oncology practice...
and the movement to tailor therapies to the individual, patients including older adults may have identified tumor-associated aberrations against which non-approved agents are available on clinical trials [20, 21]. However, this access to early phase trials by all subpopulations including older adults begins with the identification of barriers to clinical trial enrollment [22, 23]. Phase I/II trials are generally viewed as more experimental therapies of non-FDA-approved drugs with much less clinical information (sometimes, no substantial clinical data in first-in-human studies) on tolerance, toxicities, and certainly efficacy [24, 25]. Beyond the trial-mandated inclusion criteria and determination of comorbidities, organ function and performance status (using the ECOG or Karnofsky scales), the subjective perception of frailty in an older patient by the treating oncologist and research team in the clinic can manifest as a lower likelihood to consider or offer early phase trials for older adults [26].

In our study, we hope to add to the body of data on the performance of older adults on clinical trials, in this case on early phase I trials with VEGF/R targeting agents. In our experience, older patients accounted for less than 20% of patients on these phase I trials but those who participated were just as likely to achieve a clinical benefit as the adolescent and young adult patient or the middle age patients. This outcome brings to light the limitations of this study. Above all, the selection bias exists where presumably only the most ‘medically fit’ older adults ultimately received therapy on trial whereas consideration must be given to how many older adults seen in the clinic were informally not considered for the trials and how many did not progress through the formal screening process for each trial. Additionally, analyses are underway to thoroughly characterize the treatment-related toxicities and their association with clinical outcomes to be reported in the near future. Data on distribution of the older adults across dose levels within each protocol as well as the half maximal inhibitory concentration (IC50) of the select anti-VEGF/VEGFR agents that were not commercially available was not readily accessible for our review; however earlier work has demonstrated that the outcomes including incidence of treatment failure, response rate, progression free survival and overall survival were not significantly different between the patient treated on lower dose levels where the treatment dose was 25% or less of the maximum tolerated dose (MTD) versus high dose level where the treatment dose was 75% or higher of the MTD [27]. Finally, the information gathered during our data collection process highlighted the absence of universal adoption of geriatrics-specific assessment including assessments for frailty, polypharmacy, etc. We emphasize the importance of a thorough geriatric assessment of patients aged 65 and above as a part of their oncologic care particularly in the advanced cancer setting under consideration for novel therapeutics.

Indeed, Identification of clinician and patient-specific determinants to decision making on participation in an early phase trial will be crucial to improving the participation of older adults on phase I trials and removing this enrollment disparity [25]. The emergence of geriatric oncology and the emphasis on improved access for older adults to newly approved cancer therapies as well as clinical trials highlights the importance to independently study the evolution of participation of patients in the special age groups, i.e. older adults, adolescent and young adults, over the past one to two decades, an area of future study. The results of early phase clinical trials and subsequent trials of efficacy not only shape national clinical guidelines for cancer treatment but also factor heavily into patient-doctor therapeutic decision-making. Therefore having the appropriate heterogeneity among clinical trial participants to reflect the actual patient population likely to receive this therapy in the general community remains a responsibility for clinician investigators.

PATIENTS AND METHODS

Patient characteristics

We queried a prospectively maintained departmental database of patients evaluated in the Department of Investigational Cancer Therapeutics between December 1, 2004 and July 31, 2013. We identified consecutive patients with advanced solid tumors who met inclusion criteria and consequently treated on phase I clinical trials with VEGF/R inhibitors to be included in this analysis. We then separated them into 3 age-based cohorts: AYA (15–39 years), middle age (40–64 years), and older adults (65 years and above) as defined by the National Comprehensive Cancer Network (NCCN). Clinical information collected included gender, date of birth, tumor type, date of diagnosis, Eastern Cooperative Oncology Group (ECOG) performance status at start of phase I trial, start date (cycle 1, day 1) of the phase I trial, and age on the trial’s start date. This study and associated clinical trials were conducted in accordance with the guidelines of the MD Anderson Institutional Review Board and patient confidentiality was maintained following Health Insurance Portability and Accountability Act guidelines.

Treatment and evaluation

Patients included in the analysis met trial-specific inclusion criteria and received therapy on that phase I trial. Patients received care such as laboratory testing and interim clinician visits as specified by each protocol. Elements of care standard throughout the protocols were as follows. Patients underwent a baseline clinical exam with the medical oncologist along with subsequent
follow-ups prior to each cycle and as clinically warranted. Imaging (either CT, MRI, MRI PET/CT as specific by protocol) was obtained at baseline and prior to alternating treatment cycles usually at 6–8 week intervals. Imaging response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria [13, 14]. Patient remained on therapy until disease progression (radiologic progression on restaging imaging or clinical progression where the patient’s overall performance status declined before restaging imaging could be obtained), unacceptable toxicity not manageable with optimum medical therapy, patient death or withdrawal of consent. The date of death was obtained from the electronic medical record; patients lost to follow up were censored at the date of last follow-up.

Statistical analysis

Categorical variables are listed in the tables and descriptive statistics were employed to analyze continuous variables. The clinical benefit, defined as a response of stable disease (SD) ≥6 months, partial response (PR), or complete response (CR), per RECIST, was determined for each age-based cohort. We developed a contingency table analysis (two-tailed Fisher’s exact test) to examine the association between pairs of categorical variables, the three age cohorts and likelihood of achieving a clinical benefit; we calculated the odds ratios (OR) of achieving a favorable clinical benefit for the 3 age cohorts, and for older adults and AYA in comparison to the middle age cohort. Statistical analyses were carried out using statistical software (The R Foundation for Statistical Computing, version 2.15, Vienna University of Economics and Business, Vienna, Austria).

Author contributions

IMS and DSH are the PIs of the study, designed the protocol, and collected and analyzed the data. All authors conducted the research. AR performed the statistical analyses. All authors contributed to the writing of the manuscript and have read and approved the final manuscript.

CONFLICTS OF INTEREST

The authors do not have any financial or other competing interests that are related to the work described in the paper.

FUNDING

Financial support provided by NIH/NCI under award number P30CA016672 Cancer Center Support Grant (CCSG).

REFERENCES

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285:1182–1186.
2. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438:967–974.
3. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473:298–307.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335–2342.
5. Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016; 388:518–529.
6. Schmittnaegel M, Rigamonti N, Kadioglu E, Cassara A, Wyser Rmli C, Kiialainen A, Kienast V, Mueller HJ, Ooi CH, Laoui D, De Palma M. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017; 9.
7. Kurkjian C, Kim ES. Risks and benefits with bevacizumab: evidence and clinical implications. Ther Adv Drug Saf. 2012; 3:59–69.
8. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291:2720–2726.
9. Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol. 2007; 14:3328–3334.
10. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Taralovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2014/.
11. Cassidy J, Saltz LB, Giannoni BJ, Kabbinaavar FF, Hurwitz HI, Rohr UP. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol. 2010; 136:737–743.
12. Subbiah IM, Wheiler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at md anderson cancer center. Int J Cancer. 2017; 140:208–215.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, et al. New response evaluation criteria in solid tumours: revised
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205–216.

15. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J. 2005; 11:461–473.

16. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 2005; 11:449–460.

17. Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Kohne CH. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008; 26:1443–1451.

18. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP; AVEX Study Investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14:1077–1085.

19. Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, et al. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016; 34:3992–3999.

20. Subbiah V, Kurzrock R. Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. JAMA Oncol. 2016; 2:719–720.

21. Subbiah V, Bupathi M, Kato S, Livingston A, Slopis J, Anderson PM, Hong DS. Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience. 2015; 2:646–658. https://doi.org/10.18632/oncoscience.176.

22. Meropol NJ. Health policy: Overcoming cost barriers to clinical trial participation. Nat Rev Clin Oncol. 2016; 13:333–334.

23. Heller C, Balls-Berry JE, Nery JD, Erwin PJ, Littleton D, Kim M, Kuo WP. Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review. Contemp Clin Trials. 2014; 39:169–182.

24. Francillon A, Pickering G, Belorgey C. Exploratory clinical trials: implementation modes & guidelines, scope and regulatory framework. Therapie. 2009; 64:149–159.

25. Smith SK, Selig W, Harker M, Roberts JN, Hesterlee S, Leventhal D, Klein R, Patrick-Lake B, Abernethy AP. Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A Survey. PLoS One. 2015; 10:e0140232.

26. Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control. 2014; 21:209–214.

27. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010; 16:1289–1297.